[ad_1]
Genomic prediction, developer of the world's first and only polygenic disease screening tests to improve the health outcomes of IVF, announced today that it has raised $ 4.5 million through the sale of 39, preferred shares. Nimble Ventures led the oversubscription round, joined by new investors, including PeopleFund, and reinforced by previous investors from the company's first round of fundraising in early 2017.
Until now, IVF families did not have access to technology to globally reduce the risk of disease in their embryonic child, said Genomic Prediction CEO Laurent Christian Asker, Melchior Tellier. Many of these diseases are preventable. Our cost-effective polygenic logging methodology relies on old technology from industrial agriculture, but we are the first in history to develop this technology to protect the human embryo. We are privileged to have an extraordinary team of scientists and investors and a unique opportunity to protect the life, health and well-being of the IVF children conceived each year as part of the 2 million cycles of IVF. We reduce the risk of illness in children, bringing IVF to the era of information.
Genomic prediction is the first company to translate genomic predictors of polygenic disease risk into prevention and improvement of clinical IVF care. Thanks to its patented technologies for genetic testing of FIV, EP "-T and" -SEQ, Genomic Prediction is able to simultaneously detect hundreds of monogenic diseases and to clbadify human embryos according to the risk of multogene disease. This allows couples and IVF clinics to reduce the risks to the embryo of type 1 diabetes, basal cell carcinoma, ovarian cancer, heart attack, inflammatory bowel disease and other diseases. many other disorders. This screening reduces the incidence of the disease and protects the health from the start: in the embryo.
Genomic Prediction will use this new funding to develop its sales team and its data science capability. This builds on increased demand following the release and approval by the New Jersey Department of Health of the EP "-T and" -SEQ tests, as well as the signing of R & D agreements. D confidential with key distributors and industry leaders.
DO YOU WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe FREE to the newsletter Global Banking & Finance Review
Access exclusive reports to save time and money
By using this form, you accept the storage and processing of your data through this site. We will not spam, rent or sell your information.
All emails include an unsubscribe link. You can unsubscribe anytime. See our privacy policy.
Genomic Prediction has recently signed its first clinic and first client distributors and recently released a new document called Genomic Prediction of Complex Disease Risk, which quantifies some of its capabilities for predicting human polygenic disease, validated on cohorts of third-party biobanks.
I take my hat off what they do, it's a potential revolution, says Professor Simon Fishel, president of CARE Fertility Group clinics in the UK, and former deputy scientific director of the world's first IVF clinic, with fellow Nobel laureates Steptoe and Dr. Edwards.
About genomic forecasting: Genomic prediction is the inventor of GTP-P: Preimplantation genetic testing for polygenic disease, the technology behind the company's flagship EP "-T and" -QSEQ tests. The genomic forecast, incorporated on May 1, 2017, was featured in The Economist, The WSJ, and New Scientist. For more information, visit www.genomicprediction.com. Contact: [email protected].
Christian Christian Asker Melchior Tellier
+1(732)723-7672
[email protected]
Source link
